Zeon Corporation Makes Strategic Investment in Chemify to Accelerate Digital Chemistry Innovation and Drive Development of New Materials Through State-of-the-Art Automated Molecular Design and Synthesis

Contributed by: Business Wire

Logo

Tags

Software

Research

Professional Services

Pharmaceutical

Robotics

Technology

Artificial Intelligence

Health Technology

Science

Biotechnology

Finance

Health

HEALTH

More Like This

Researchers at Chemify’s first Chemifarm—a fully automated chemistry facility regarded as the world’s most advanced laboratory for molecular design and synthesis, which opened in Glasgow, Scotland in June of 2025. Chemify, the deep-tech pioneer fusing chemistry, robotics, computation, and Chemputation—Chemify’s purpose-built AI to digitize molecule creation—announced today it has raised over $50 million in Series B funding to help accelerate its mission of becoming the global leader in digital chemistry, molecular design and manufacturing. Co-led by Wing Venture Capital and Insight Partners, the financing will scale Chemify’s Chemputation platform and Chemifarm facilities, transforming how molecules are designed and made for medicines and advanced materials.

Chemify Raises More Than $50 Million in Oversubscribed Series B to Drive Global Expansion of Digital Chemistry and Discovery

https://chemify.reportablenews.com/pr/chemify-launches-the-world-s-first-chemputation-facility-revolutionizing-molecular-design-and-manufacture

Chemify Launches the World's First Chemputation Facility Revolutionizing Molecular Design and Manufacture

Lee Cronin, CEO and founder of Chemify, the deep-tech pioneer of Chemputation – a technological breakthrough that integrates AI- and ML-driven molecular discovery and automated, robotic synthesis – has published three peer-reviewed research papers in close succession, constituting a technological tour de force that validates Chemputation as a new paradigm for how small molecule-drugs and materials are discovered, designed and manufactured. The three publications in PNAS, Nature Communications Chemistry and Nature Communications Biology describe how the Chemputation AI platform can understand and execute instructions to make new molecules from scientific literature, produce them iteratively and how this could be applied to cancer research.

Chemify Founder Publishes Three Papers Validating Chemputation To Reimagine New Chemical Discovery and Development

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Dr. Alastair Leighton has joined as Chief Operating Officer (COO). With almost three decades in the biopharma industry working at leading global pharmaceutical companies, Dr. Leighton brings a wealth of experience in manufacturing, supply chain operations and commercial strategy. (Photo: Business Wire)

Chemify Hires Biopharma Veteran Dr. Alastair Leighton as Chief Operating Officer

Chemify Receives an Additional Grant to Accelerate Digital Chemistry Small-Molecule Discovery for Tuberculosis

Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced today that Michael Bell has joined as Chief Technology Officer. As a well-known technology veteran in the digital computing industry who helped lead the creation of the Apple iPhone and the launch of Intel’s mobile devices, Mr. Bell will help accelerate the capabilities of Chemify’s digital chemistry platform and the world’s first chemical programming language. (Photo: Business Wire)

Former Apple and Intel Executive Michael Bell Joins Chemify as Chief Technology Officer

Chemify and Sanacor Collaborate to Discover and Develop Small Molecule Therapies for Cardiometabolic Diseases

Merck and ChemLex Sign Memorandum of Understanding to Advance Automated Chemistry and Technological Innovation